Coeptis Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Coeptis Therapeutics, Inc. carries a market capitalization of 57.63M, placing it among publicly traded companies globally. Its enterprise value stands at 49.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 57.63M |
| Enterprise Value | 49.17M |
Share Statistics
Coeptis Therapeutics, Inc. currently has 5.75M shares outstanding.
| Shares Outstanding | 5.75M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 40.16, and the price-to-book ratio stands at -0.50.
| PE Ratio | N/A |
| PS Ratio | 40.16 |
| PB Ratio | -0.50 |
| P/TBV Ratio | 4.16 |
| P/FCF Ratio | -6.36 |
| P/OCF Ratio | -6.36 |
Enterprise Valuation
| EV / Sales | 36.07 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Coeptis Therapeutics, Inc. maintains a current ratio of 4.16, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.91, indicating elevated leverage, while an interest coverage ratio of -18.40 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.16 |
| Quick Ratio | 3.60 |
| Debt / Equity | 1.91 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | -18.40 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -87.06 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Coeptis Therapeutics, Inc.'s stock has gained approximately 78.45484% over the past 52 weeks. The 50-day moving average sits at 12.25, while the 200-day moving average is 13.72.
| Beta (5Y) | N/A |
| 52-Week Price Change | 78.45484% |
| 50-Day Moving Average | 12.25 |
| 200-Day Moving Average | 13.72 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Coeptis Therapeutics, Inc. generated 1.36M in revenue and converted that into -10.91M in net income, yielding earnings per share of -3.20. EBITDA reached -11.82M, while operating income came in at -13.04M.
| Revenue | 1.36M |
| Gross Profit | 1.18M |
| Operating Income | -13.04M |
| Pretax Income | -12.28M |
| Net Income | -10.91M |
| EBITDA | -11.82M |
| EBIT | -13.04M |
| Earnings Per Share (EPS) | -3.20 |
Balance Sheet
Coeptis Therapeutics, Inc. holds 6.35M in cash and equivalents against 268,875.00 in total debt, resulting in a net debt position of -5.42M. Total book value stands at -109.95M, with working capital of 5.58M providing operational flexibility.
| Cash & Cash Equivalents | 6.35M |
| Total Debt | 268,875.00 |
| Net Debt | -5.42M |
| Equity (Book Value) | -109.95M |
| Book Value Per Share | -28.62 |
| Working Capital | 5.58M |
Cash Flow
Coeptis Therapeutics, Inc. produced -8.60M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.60M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.60M |
| FCF Per Share | -2.24 |
Margins
Coeptis Therapeutics, Inc. operates with a gross margin of 86.75, reflecting its pricing power and cost economics. The operating margin of -956.94 and net profit margin of -800.38 provide insight into operational efficiency.
| Gross Margin | 86.75 |
| Operating Margin | -956.94 |
| Pretax Margin | -900.72 |
| Profit Margin | -800.38 |
| EBITDA Margin | -867.24 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -25.11 |
| FCF Yield | -15.72 |
Stock Splits
Coeptis Therapeutics, Inc.'s most recent stock split took place on December 31, 2024 with a 20:1 split ratio.
| Last Split Date | 12/31/2024 |
| Split Ratio | 20:1 |
Scores
Coeptis Therapeutics, Inc. posts an Altman Z-Score of 3.35, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.35 |